Cisplatin plus etoposide versus other platin‐based regimens for patients with extensive small‐cell lung cancer: a systematic review and meta‐analysis of randomised, controlled trials

Jiang, Lei; Yang, Kehu; Guan, Quanlin; Mi, Denghai; Wang, Jizeng

doi:10.1111/j.1445-5994.2012.02821.x

Cited by 21 publications

(23 citation statements)

References 42 publications

(107 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data from our analysis indicate that there is insufficient evidence to prove the superiority of EP/CP over other multidrug protocols. This negative result is similar to the parallel data from Jiang et al ., who compared the efficacy of EP with other platin‐based regimens in patients with small‐cell lung carcinoma …”

Section: Discussionmentioning

confidence: 99%

Chemotherapy with cisplatin or carboplatin in combination with etoposide for small-cell esophageal cancer: a systemic analysis of case series

et al. 2013

View full text Add to dashboard Cite

Chemotherapy has been the first-choice treatment for small-cell esophageal cancer (SCEC), etoposide plus cisplatin or carboplatin (EP/CP) is the most commonly recommended chemotherapeutical strategy. However, the choice of chemotherapy in treating SCEC has not been validated by studies of large cohorts of cases because of the rarity of the malignancy, and the efficacy superiority of EP/CP over other chemotherapy combinations has not been confirmed. The present case series analysis was conducted to address the above issues. Reported studies of SCEC patients were retrieved. Case series with more than five patients were enrolled. Eight patients treated in our institute were also included as another case series. Data pertaining to clinical stages, treatment regimens, and survival time were collected and analyzed. Altogether, 19 SCEC case series were enrolled, including 164 male and 61 female patients with a median age of 63.5 years. The follow-up time ranged from 0.1 to 221 months (median 12.3 months). The median survival time (MST) was 19 months for limited disease (LD) patients (124 cases) and 9 months for extensive disease (ED) patients (88 cases) (P<0.001). For LD patients, MST was obviously prolonged by chemotherapeutical regimens (20 vs. 10 months, P<0.01), whereas this superiority was not proved in ED patients (10 vs. 10 months, P>0.05). EP/CP did not result in significantly longer MST, compared with that of the cases treated by other chemotherapy combinations (P>0.05, for either LD or ED cases). Chemotherapy prolongs the survival time of the LD SCEC patients, which indicates that chemotherapeutical treatment is effective for SCEC. EP/CP, as commonly recommended multidrug chemotherapy regimen, is not superior to other chemotherapy combinations.

show abstract

Section: Discussionmentioning

confidence: 99%

Chemotherapy with cisplatin or carboplatin in combination with etoposide for small-cell esophageal cancer: a systemic analysis of case series

et al. 2013

View full text Add to dashboard Cite

show abstract

“…To improve the chemotherapeutic efficacy and overcome chemoresistance, several studies have explored the incorporation of novel agents and creation of new regimens. Unfortunately, there is no strong evidence that other platinum-based regimens have any clinical advantage over EP [15]. Jiang et al reported that irinotecan/cisplatin might improve OS with overall HR of 0.87 (P = 0.01), but they could not detect a significant effect of irinotecan/cisplatin versus EP on survival (P = 0.12) after exclusion of a Japanese trial [16] due to heterogeneity [15].…”

Section: Discussionmentioning

confidence: 99%

“…Unfortunately, there is no strong evidence that other platinum-based regimens have any clinical advantage over EP [15]. Jiang et al reported that irinotecan/cisplatin might improve OS with overall HR of 0.87 (P = 0.01), but they could not detect a significant effect of irinotecan/cisplatin versus EP on survival (P = 0.12) after exclusion of a Japanese trial [16] due to heterogeneity [15]. Lee et al [17] reported that gemcitabine/carboplatin did not improve survival benefits, but did increase grade 3/4 hematological toxicities.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer

Lee

Koo

et al. 2015

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…However, long-term survival in SCLC patients has not been satisfactory (3)(4)(5). Etoposide plus platinum (EP) is currently the standard first-line treatment used in SCLC to obtain longer overall survival (OS) and progression-free survival, although numerous chemotherapeutic regimens comprising various drugs have been investigated and tested in clinical trials (6,7).…”

Section: Introductionmentioning

confidence: 99%

Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis

Yang

Liu

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. This study was conducted to compare the efficacy and safety of ifosfamide plus etoposide plus platinum (IEP) to that of etoposide plus platinum (EP) in patients with previously untreated small-cell lung cancer (SCLC). The Cochrane Library, Embase, MEDLINE and Chinese Biomedical Literature databases were searched to identify all randomized controlled trials comparing IEP to EP in patients with histologically proven SCLC. Two investigators independently assessed the quality of the relevant trials and extracted data. We analyzed the data using Review Manager software, version 4.2.8. A total of 4 trials with 447 previously untreated SCLC patients were included in this meta-analysis. The results of the meta-analysis indicated that there were no significant differences in the overall response [relative risk (RR) = 1.07, 95% confidence interval (CI): 0.97-1.19], 1-year survival rate (RR=1.22, 95% CI: 0.96-1.55) and 2-year survival rate (RR=1.52, 95% CI: 0.75-3.07) between the IEP and EP regimens. However, there were significant differences between the IEP and EP regimens regarding the incidence of grade 3̸4 neutropenia (RR=1.52, 95% CI: 1.07-2.17) and grade 3̸4 vomiting (RR=1.78, 95% CI: 1.02-3.11). In conclusion, our results suggested that IEP is not superior to EP regimen for the treatment of previously untreated SCLC, whereas the IEP regimen is associated with more severe hematological and gastrointestinal toxicities compared to EP. Therefore, the use of ifosfamide in multimodality treatment regimens requires further investigation.

show abstract

Cisplatin plus etoposide versus other platin‐based regimens for patients with extensive small‐cell lung cancer: a systematic review and meta‐analysis of randomised, controlled trials

Cited by 21 publications

References 42 publications

Chemotherapy with cisplatin or carboplatin in combination with etoposide for small-cell esophageal cancer: a systemic analysis of case series

Chemotherapy with cisplatin or carboplatin in combination with etoposide for small-cell esophageal cancer: a systemic analysis of case series

Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer

Benefit from ifosfamide treatment in small-cell lung cancer: A meta-analysis

Contact Info

Product

Resources

About